Dexcom has made a significant move above resistance, assuming today's gains hold. It is still early, and volume looks good, so if the price stays up it should be a solid volume breakout.
This stock held up well while the market was tanking.
Price target is an estimate (always). I am using a trailing stop loss on this one.
Disclosure: Long.
Dexcom rallied off the lows of the range and is now consolidating near the top of a year-long range.
Watching this one closely. About a 3:1 reward to risk with a stop loss below the consolidation and a target between 196 and 200. Want to see high volume on the consolidation breakout to show there is likely enough conviction to break above the range high as well....
DXCM flirting with new highs while RSI looks pretty constructive. This looks like it might run a bit so while it might be a nice quick momentum play there is probably a lot of long term appeal here. This also applies to AYX which I just posted.
Symbol DXCM
setup flag
Upcoming Earnings Jan 29, 2019 (EST) Feb 21, 2019 (EST)
Horizontal S&R: yes 138
Channel S&R: no
MA S&R: yes bounced off of 20ma
>200ma: yes
Volume confirmation: ok
Candle Confirmation: yes morning star
Stoch Divergence: no
Reg Trendline >85: no
Short Float: 7%
Entry 152
Stop 137
Price Target 182
Risk / Reward: 1:2
Zacks...
Clearly, that Dec 24 route was the clear buying opportunity, You would've been +40% by now.
Is it too late? I'd say NO.
If you have the ability to invest on this, and of course, have an awareness on all the geopolitical factors. I think this is a win.
If you want to swing, it's also up to you.
Here's the thing
1) Let's be clear, DexCom is the leader on CGM...
Industry:Medical Equipment, Supplies & Distribution
Employees:2800
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
DXCM
